Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

doi:10.1200/JCO.2010.28.9678

Article

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Oct 2010

Fischer Thomas, Stone Richard M, Deangelo Daniel J, Galinsky Ilene, Estey Elihu, Lanza Carlo, Fox Edward, Ehninger Gerhard, Feldman Eric J, Schiller Gary J, Klimek Virginia M, Nimer Stephen D, Gilliland D Gary, Dutreix Catherine, Huntsman-Labed Alice, Virkus Jodi, Giles Francis J

Abstract excerpt

PURPOSE: Mutations leading to constitutive activation of the FMS-like tyrosine kinase 3 receptor (FLT3) occur in blasts of 30% of patients with acute myeloid leukemia (AML). Midostaurin (PKC412; N-benzoylstaurosporin) is a multitargeted tyrosine kinase inhibitor, with demonstrated activity in patients with AML/myelodysplastic syndrome (MDS) with FLT3 mutations. PATIENTS AND METHODS: Ninety-five patients with AML...

Topics

Administration, Oral
Aged
Antineoplastic Agents
Female
Humans
Leukemia, Myeloid, Acute
Male
Mutation

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Abstract excerpt

Topics

Discuss the evidence

Related research